<p>(A) EGFR mutations and (B) ALK rearrangements. <sup>a</sup><i>p</i>-values were calculated by linear-by-linear association test.</p
<p>Kaplan-Meier curves of (A) PFS and (B) OS according to the quantity of <i>de novo</i> EGFR T790M ...
Comparisons of the EGFR mutational and ALK translocation results between the EBUS-GS and surgical sp...
Overall survival by NSCLC histology, predictive biomarker testing, and mutation status (EGFR mutatio...
<p>COPD, chronic obstructive pulmonary disease; EGFR, epidermal growth factor receptor; ALK, anaplas...
<p>Epidermal growth factor receptor (EGFR) mutation spectrum among patients with EGFR-mutant lung ad...
<p>EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; EML4, echinoderm microtu...
Background: Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) tr...
Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutatio...
Introduction: Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutationa...
<p>(A) <i>EGFR</i> mutation status across all NSCLC samples is shown. Black segment in the inner cir...
<p>Kaplan-Meier analysis comparing TTF of patient groups with and without clearance of CTC during th...
BACKGROUND: EML4-ALK fusion gene is found in only a small subset (2-6%) of non-small cell lung cance...
EGFR mutation testing rates by year in 12,148 patients who underwent EGFR testing.</p
Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutatio...
<p>Association between <i>EGFR</i>-mutant status and Erlotinib treatment with all-cause survival amo...
<p>Kaplan-Meier curves of (A) PFS and (B) OS according to the quantity of <i>de novo</i> EGFR T790M ...
Comparisons of the EGFR mutational and ALK translocation results between the EBUS-GS and surgical sp...
Overall survival by NSCLC histology, predictive biomarker testing, and mutation status (EGFR mutatio...
<p>COPD, chronic obstructive pulmonary disease; EGFR, epidermal growth factor receptor; ALK, anaplas...
<p>Epidermal growth factor receptor (EGFR) mutation spectrum among patients with EGFR-mutant lung ad...
<p>EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; EML4, echinoderm microtu...
Background: Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) tr...
Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutatio...
Introduction: Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutationa...
<p>(A) <i>EGFR</i> mutation status across all NSCLC samples is shown. Black segment in the inner cir...
<p>Kaplan-Meier analysis comparing TTF of patient groups with and without clearance of CTC during th...
BACKGROUND: EML4-ALK fusion gene is found in only a small subset (2-6%) of non-small cell lung cance...
EGFR mutation testing rates by year in 12,148 patients who underwent EGFR testing.</p
Treatment patterns by predictive biomarker testing (EGFR mutation and ALK rearrangement) and mutatio...
<p>Association between <i>EGFR</i>-mutant status and Erlotinib treatment with all-cause survival amo...
<p>Kaplan-Meier curves of (A) PFS and (B) OS according to the quantity of <i>de novo</i> EGFR T790M ...
Comparisons of the EGFR mutational and ALK translocation results between the EBUS-GS and surgical sp...
Overall survival by NSCLC histology, predictive biomarker testing, and mutation status (EGFR mutatio...